Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Talphera (NASDAQ:TLPH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Profitability
This table compares Incannex Healthcare and Talphera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incannex Healthcare | N/A | -81.01% | -76.11% |
| Talphera | N/A | -87.28% | -51.36% |
Valuation & Earnings
This table compares Incannex Healthcare and Talphera”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incannex Healthcare | $90,000.00 | 453.53 | -$46.88 million | ($1.55) | -2.20 |
| Talphera | $1,000.00 | 60,210.96 | -$14.29 million | ($0.27) | -4.30 |
Talphera has lower revenue, but higher earnings than Incannex Healthcare. Talphera is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Incannex Healthcare has a beta of 6.97, meaning that its share price is 597% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Incannex Healthcare and Talphera, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incannex Healthcare | 1 | 0 | 1 | 0 | 2.00 |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 427.86%. Talphera has a consensus target price of $3.00, indicating a potential upside of 158.62%. Given Incannex Healthcare’s higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Talphera.
Summary
Talphera beats Incannex Healthcare on 8 of the 13 factors compared between the two stocks.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
